Thomas Michael Tamberrino Purchases 3,755 Shares of Profound Medical (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN – Get Free Report) insider Thomas Michael Tamberrino acquired 3,755 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was purchased at an average cost of C$9.44 per share, for a total transaction of C$35,447.20. Following the completion of the acquisition, the insider owned 53,573 shares in the company, valued at approximately C$505,729.12. This represents a 7.54% increase in their ownership of the stock.

Profound Medical Stock Performance

PRN stock traded down C$0.17 during trading hours on Monday, hitting C$9.03. 6,769 shares of the stock were exchanged, compared to its average volume of 16,137. The company has a current ratio of 6.46, a quick ratio of 14.98 and a debt-to-equity ratio of 14.82. The firm has a market capitalization of C$328.13 million, a P/E ratio of -9.12 and a beta of 1.30. The company has a 50-day simple moving average of C$9.87 and a two-hundred day simple moving average of C$9.36. Profound Medical Corp. has a 12 month low of C$5.23 and a 12 month high of C$12.40.

Get Profound Medical alerts:

Profound Medical (TSE:PRN – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share (EPS) for the quarter. The business had revenue of C$3.53 million during the quarter. Profound Medical had a negative net margin of 170.92% and a negative return on equity of 62.45%. On average, analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James Financial raised shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, July 27th. Eight investment analysts have rated the stock with a Buy rating, sixteen have issued a Moderate Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Profound Medical has an average rating of “Moderate Buy” and a consensus target price of C$9.03.

Get Our Latest Stock Report on Profound Medical

About Profound Medical

(Get Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

Featured Stories

• Five stocks we like better than Profound Medical
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.